



RaQualia
innovators for life

**5-HT₄ Partial Agonist for
Gastroesophageal Reflux Disease**

Worldwide Partnering Opportunity

1. Executive Summary

- RQ-00000010 is a 5-HT₄ receptor partial agonist for the treatment of gastroesophageal reflux disease (GERD).
 - Potent and highly selective 5-HT₄ partial agonist
 - Exhibit exceptionally potent oral GI motility activity in dogs
 - » Increase in gastric motility with a minimum effective dose of 1.0 µg/kg
 - » Accelerate gastric emptying with a minimum effective dose of 0.1 µg/kg
 - RQ-00000010 is up to 10,000 times more potent than cisapride in our GI efficacy models in dogs and with no QTc liability.
- RQ-00000010 is ready for Phase 1 (Time to FIH is estimated to be 9 months).
 - One-month GLP general toxicity studies completed and no significant safety issues for clinical studies including ECG parameters.
 - » Rat NOAEL: 10 and 30 mg/kg/day for males and females, respectively
 - » Dog NOAEL: 30 mg/kg/day
 - PK/ADME profiles determined.
 - Projected human efficacy dose is 0.03–0.3 mg QD or BID.
 - Key intermediates are available for API synthesis.
- IP status: COM* expiry over 20 years including up to 5 years extension

*: Composition of Matter

2. Table of Contents

Title	Slide No.
1. Executive Summary	2
2. Table of Contents	3
3. Product Concept	4
4. Unmet Medical Needs	6
5. Market Opportunity	7
6. Mechanism of Action	8
7. Compound Attributes	10
7.1. Compound Information	11
7.2. Nonclinical Pharmacology	12
7.3. Nonclinical Pharmacokinetics and Drug Metabolism	18
7.4. Toxicology and Safety Pharmacology	24
7.5. List of Nonclinical Studies	27
7.6. Summary of RQ-00000010	30
8. Draft Clinical Development Plan (until POC)	31
9. Competitors	32

弊社とのパートナーリングをご希望の方は「[お問い合わせ](#)」よりご連絡ください

ラクオリア創薬株式会社

Copyright RaQualia Pharma Inc. All Rights Reserved. 2011